Description

FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION, VETERINARY USE, OR IN VIVO DIAGNOSTIC PURPOSES.

Product Overview: DSIP (Delta Sleep-Inducing Peptide)

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood during low-frequency electrical stimulation of the thalamus. Operating as a neuromodulator, DSIP crosses the blood-brain barrier to regulate slow-wave (delta) sleep architecture, modulate hypothalamic-pituitary-adrenal (HPA) axis stress responses, and alter central neurotransmitter turnover. DSIP serves as a foundational research compound for studying sleep neurobiology, stress adaptation, circadian rhythm synchronization, and neuroendocrine regulation.

Primary Purpose: Research settings utilize DSIP primarily to investigate central sleep architecture and stress neurobiology—specifically by modulating delta-wave sleep generation, normalizing ACTH/corticosterone secretion, and protecting central neural pathways from oxidative stress.

Primary Research Applications & Reasons for Study

Delta-Wave Sleep Induction: Promoting slow-wave delta EEG activity and modulating non-REM sleep cycles without suppressing REM sleep parameters.
HPA Axis & Stress Normalization: Suppressing hyper-stimulated Adrenocorticotropic Hormone (ACTH) and cortisol/corticosterone secretion in chronic stress models.
Luteinizing Hormone (LH) Release: Modulating basal pituitary LH secretion dynamics and neuroendocrine pulsatility in endocrine assays.
Central Antioxidant Protection: Evaluating the reduction of lipid peroxidation and preservation of endogenous antioxidant enzymes (superoxide dismutase) under hypoxic or toxic stress.

Expected Research Results & Timeline Metrics

Phase 1 / Hours 1–6
Acute EEG Rhythm Shifts: Rapid increase in synchronized slow-wave (delta) spindle activity on electroencephalogram (EEG) readouts within 1–4 hours of central administration.
Phase 2 / Days 1–7
HPA Axis Dampening: Statistically significant reductions in elevated stress-induced glucocorticoids, stabilization of sleep-wake architecture, and lowered oxidative stress markers.
Phase 3 / Weeks 2–4
Circadian Normalization & Neuroprotection: Long-term synchronization of endogenous physiological rhythms, enhanced resistance to metabolic stress, and normalized neuroendocrine baseline parameters.

Key Research Benefits

Physiological Sleep Modulator: Promotes natural sleep architecture without inducing sedative-hypnotic dependency, motor ataxia, or REM suppression.
Stress Adaptogen Model: Acts as a regulatory buffer to dampen excessive corticosterone spikes under physical and psychological stress models.
Blood-Brain Barrier Permeability: Amphiphilic nonapeptide structure allows efficient central nervous system entry across the BBB.
Versatile Neuroendocrine Tool: Key candidate for investigating sleep disorders, stress-induced metabolic dysfunction, and opioid withdrawal mechanics.

Regulatory Compliance & Legal Research Disclaimer

THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research compounds.

Additional information

Size	5 mg